BR112012002336A2 - compostos aza-heterocíclicos - Google Patents
compostos aza-heterocíclicosInfo
- Publication number
- BR112012002336A2 BR112012002336A2 BR112012002336A BR112012002336A BR112012002336A2 BR 112012002336 A2 BR112012002336 A2 BR 112012002336A2 BR 112012002336 A BR112012002336 A BR 112012002336A BR 112012002336 A BR112012002336 A BR 112012002336A BR 112012002336 A2 BR112012002336 A2 BR 112012002336A2
- Authority
- BR
- Brazil
- Prior art keywords
- azaheterocyclic compounds
- azaheterocyclic
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23217909P | 2009-08-07 | 2009-08-07 | |
| PCT/US2010/042844 WO2011017009A1 (en) | 2009-08-07 | 2010-07-22 | Novel azaheterocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012002336A2 true BR112012002336A2 (pt) | 2016-05-31 |
Family
ID=42543449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012002336A BR112012002336A2 (pt) | 2009-08-07 | 2010-07-22 | compostos aza-heterocíclicos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9023847B2 (pt) |
| EP (1) | EP2462141B1 (pt) |
| JP (1) | JP5763636B2 (pt) |
| KR (1) | KR20120059525A (pt) |
| CN (1) | CN102471338B (pt) |
| AR (1) | AR077800A1 (pt) |
| AU (1) | AU2010281503B2 (pt) |
| BR (1) | BR112012002336A2 (pt) |
| CA (1) | CA2770155C (pt) |
| EA (1) | EA020302B1 (pt) |
| ES (1) | ES2654332T3 (pt) |
| IL (1) | IL217927A (pt) |
| MX (1) | MX2012001413A (pt) |
| SG (1) | SG178273A1 (pt) |
| WO (1) | WO2011017009A1 (pt) |
| ZA (1) | ZA201201653B (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
| US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| EP2809671B1 (en) * | 2012-01-30 | 2016-01-13 | Cephalon, Inc. | Imidazo [4, 5 - b]pyridine derivatives as alk and jak modulators for the treatment of proliferative disorders |
| US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
| CN103012428A (zh) * | 2013-01-08 | 2013-04-03 | 中国药科大学 | 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途 |
| KR20160003115A (ko) * | 2013-04-30 | 2016-01-08 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 제스트 인핸서 상동체 2 억제제 |
| US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
| US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| CN110483366B (zh) * | 2018-05-14 | 2022-09-16 | 中国医学科学院药物研究所 | 吲哚类化合物及其制备方法、药物组合物和用途 |
| CN111269167A (zh) * | 2018-12-05 | 2020-06-12 | 中国医学科学院药物研究所 | N-酰基磺酰胺盐类FBPase抑制剂、其制备方法、药物组合物及用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| US7696225B2 (en) * | 2003-01-06 | 2010-04-13 | Osi Pharmaceuticals, Inc. | (2-carboxamido)(3-Amino) thiophene compounds |
| EP1615906A1 (en) | 2003-04-03 | 2006-01-18 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| WO2005033086A1 (en) | 2003-09-30 | 2005-04-14 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| WO2005039506A2 (en) | 2003-10-24 | 2005-05-06 | Exelixis, Inc. | P70s6 kinase modulators and method of use |
| WO2005054237A1 (en) | 2003-11-21 | 2005-06-16 | Novartis Ag | 1h-imidazoquinoline derivatives as protein kinase inhibitors |
| KR20060123463A (ko) | 2003-12-09 | 2006-12-01 | 더 거번먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 레프리젠티드 바이 더 세크러터리 오브 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 | 면역 반응을 억제하거나 증식성 장애를 치료하는 방법들 |
| CA2563699C (en) | 2004-04-23 | 2014-03-25 | Exelixis, Inc. | Kinase modulators and method of use |
| ATE543821T1 (de) | 2004-12-28 | 2012-02-15 | Exelixis Inc | Ä1h-pyrazoloä3,4-düpyrimidin-4-ylü-piperidin- oder piperazinverbindungen als serin-threonin- kinasemodulatoren (p70s6k, atk1 und atk2) zur behandlung von immunologischen, entzündlichen und proliferativen erkrankungen |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| RU2435769C2 (ru) * | 2005-05-20 | 2011-12-10 | Вертекс Фармасьютикалз Инкорпорейтед | Пирролопиридины, полезные в качестве ингибиторов протеинкиназы |
| US8343953B2 (en) | 2005-06-22 | 2013-01-01 | Astex Therapeutics Limited | Pharmaceutical compounds |
| CA2633035C (en) * | 2005-12-15 | 2016-05-10 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and their uses |
| UA99284C2 (ru) | 2007-05-11 | 2012-08-10 | Елі Ліллі Енд Компані | ИНГИБИТОРЫ р70 S6-КИНАЗЫ |
| WO2010045451A1 (en) * | 2008-10-16 | 2010-04-22 | Glaxosmithkline Llc | Pyrrolopyrimidine compounds |
-
2010
- 2010-07-22 WO PCT/US2010/042844 patent/WO2011017009A1/en active Application Filing
- 2010-07-22 US US13/388,690 patent/US9023847B2/en active Active
- 2010-07-22 EA EA201200247A patent/EA020302B1/ru not_active IP Right Cessation
- 2010-07-22 ES ES10737437.3T patent/ES2654332T3/es active Active
- 2010-07-22 JP JP2012523635A patent/JP5763636B2/ja not_active Expired - Fee Related
- 2010-07-22 CN CN201080034913.5A patent/CN102471338B/zh active Active
- 2010-07-22 SG SG2012008090A patent/SG178273A1/en unknown
- 2010-07-22 CA CA2770155A patent/CA2770155C/en active Active
- 2010-07-22 EP EP10737437.3A patent/EP2462141B1/en active Active
- 2010-07-22 KR KR1020127005797A patent/KR20120059525A/ko not_active Application Discontinuation
- 2010-07-22 BR BR112012002336A patent/BR112012002336A2/pt not_active IP Right Cessation
- 2010-07-22 AU AU2010281503A patent/AU2010281503B2/en not_active Ceased
- 2010-07-22 MX MX2012001413A patent/MX2012001413A/es active IP Right Grant
- 2010-08-06 AR ARP100102893A patent/AR077800A1/es not_active Application Discontinuation
-
2012
- 2012-02-02 IL IL217927A patent/IL217927A/en active IP Right Grant
- 2012-03-06 ZA ZA2012/01653A patent/ZA201201653B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL217927A (en) | 2015-09-24 |
| IL217927A0 (en) | 2012-03-29 |
| CN102471338A (zh) | 2012-05-23 |
| EA020302B1 (ru) | 2014-10-30 |
| AU2010281503A1 (en) | 2012-03-22 |
| JP2013501713A (ja) | 2013-01-17 |
| JP5763636B2 (ja) | 2015-08-12 |
| EA201200247A1 (ru) | 2012-09-28 |
| CA2770155A1 (en) | 2011-02-10 |
| ZA201201653B (en) | 2012-11-28 |
| CN102471338B (zh) | 2014-07-02 |
| WO2011017009A1 (en) | 2011-02-10 |
| SG178273A1 (en) | 2012-03-29 |
| KR20120059525A (ko) | 2012-06-08 |
| AU2010281503B2 (en) | 2016-01-28 |
| AR077800A1 (es) | 2011-09-21 |
| US9023847B2 (en) | 2015-05-05 |
| US20120277228A1 (en) | 2012-11-01 |
| EP2462141B1 (en) | 2017-09-27 |
| MX2012001413A (es) | 2012-03-21 |
| EP2462141A1 (en) | 2012-06-13 |
| ES2654332T3 (es) | 2018-02-13 |
| CA2770155C (en) | 2017-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2017026I2 (el) | Τετρακυκλικη ενωση | |
| SMT201600008B (it) | Composti di piridazinone | |
| BR112012006859A2 (pt) | compostos | |
| DK2427449T3 (da) | Vinylindazolylforbindelser | |
| SMT201600045B (it) | Composti tetraciclinici c7-fluoro sostituiti | |
| DK2288375T3 (da) | Pegylerede insulin-lispro-forbindelser | |
| BRPI0920707A2 (pt) | compostos | |
| DK2242759T3 (da) | Forbindelser | |
| BRPI1008774A2 (pt) | espiroamida substituída | |
| DE112010002949A5 (de) | Kupplungstastpunkte | |
| BRPI1013614A2 (pt) | compostos substituídos de espiro-amida | |
| BRPI1005525A2 (pt) | compostos de azaazuleno | |
| BRPI1013868A2 (pt) | composto diaciletilenodiamina | |
| BRPI1008827A2 (pt) | deisobutenizador | |
| BR112012002336A2 (pt) | compostos aza-heterocíclicos | |
| BRPI1014968A2 (pt) | subalargador | |
| FIC20230025I1 (fi) | neratinibi | |
| DK2297162T3 (da) | Forbindelser | |
| DE112010002728A5 (de) | Turboinhalator | |
| UY33156A (es) | Nuevos compuestos tienopirrol | |
| DE112009005323A5 (de) | Hebelarmprüfmaschine | |
| DE112009005462T8 (de) | Lenkungsssteuervorrichtung | |
| BR112012004964A2 (pt) | girocóptero | |
| BRPI1008070A2 (pt) | tricianoboratos | |
| BRPI0916432A2 (pt) | compostos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2372 DE 21-06-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |